Five Year Follow-Up Data Of Pfizer’s CROWN Trial Shows Prolonged Progression-Free Survival In ALK-Positive Advanced Lung Cancer – Middle East Business News And Information
(MENAFN– Mid-East) An unprecedented 60% of patients remain alive without disease progression after five years. Updated results show continued 81%…










